Acceleron to sell 4.65 million shares in IPO between $13.00-$15.00

Citigroup, Leerink Swann are bookrunners; Piper Jaffray, JMP assist

By Devika Patel

Knoxville, Tenn., Sept. 6 - Acceleron Pharma Inc. will sell 4.65 million common shares in its initial public offering with a greenshoe of 697,500 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced on Aug. 7.

The shares will be sold at a price expected to be between $13.00 and $15.00 per share.

Citigroup and Leerink Swann are the joint bookrunning managers. Piper Jaffray and JMP Securities are the co-managers.

Proceeds will be used for clinical development of dalantercept, to advance and to expand preclinical research, for general and administrative expenses, for potential future development programs, for early stage research and development, for capital expenditures, for working capital and for other general corporate purposes.

Celgene Corp. will invest $10 million in a separate private placement of stock at a price per share equal to the initial public offering.

Based in Cambridge, Mass., Acceleron is a clinical-stage biopharmaceutical company. The company intends to list its common stock on the Nasdaq under the symbol "XLRN."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.